Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 344 followers
Latest posts
Last updated about 12 hours ago
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
about 12 hours ago
The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor...
The future of RAS inhibitors
about 13 hours ago
Revolution Medicines recently made history with the approval of its RAS inhibitor...
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
about 14 hours ago
The announcement from Merck & Co. and Moderna last month that their...
Singapore launches biotech-focused Boston hub to build on 'centuries-old bond'
about 15 hours ago
Officials rubbed shoulders with business leaders in a 19th-floor meeting room to...
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
about 15 hours ago
Takeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving...
Scientists boycott American Diabetes Association as fallout of June conference fracas escalates
about 16 hours ago
Following the removal of five scientists from its annual conference in June...
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
about 19 hours ago
In his first interview after taking the reins of the FDA’s Oncology...
The signal that changes everything: understanding MRD in oncology drug development
1 day ago
Is the cancer truly gone?
Moving NAMs from Progress to Practice: Building the Foundation for Broader Adoption
1 day ago
The future of NAMs depends on more than innovation. Learn how sourcing...
Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
1 day ago
Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment...
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
1 day ago
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder...
Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal
1 day ago
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate...